Clinical Trial Update: Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

Phase 3 trial of aripiprazole for agitation in Alzheimer's disease-associated dementia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Agitation Associated With Dementia of the Alzheimer's Type | Phase 3 | Status: TERMINATED